Literature DB >> 32735781

SUMOylation of Enzymes and Ion Channels in Sensory Neurons Protects against Metabolic Dysfunction, Neuropathy, and Sensory Loss in Diabetes.

Nitin Agarwal1, Francisco J Taberner1, Daniel Rangel Rojas1, Mirko Moroni2, Damir Omberbasic2, Christian Njoo1, Alexandra Andrieux3, Pooja Gupta1, Kiran K Bali1, Esther Herpel4, Faramarz Faghihi1, Thomas Fleming5, Anne Dejean3, Stefan G Lechner1, Peter P Nawroth5, Gary R Lewin2, Rohini Kuner6.   

Abstract

Diabetic peripheral neuropathy (DPN) is a highly frequent and debilitating clinical complication of diabetes that lacks therapies. Cellular oxidative stress regulates post-translational modifications, including SUMOylation. Here, using unbiased screens, we identified key enzymes in metabolic pathways and ion channels as novel molecular targets of SUMOylation that critically regulated their activity. Sensory neurons of diabetic patients and diabetic mice demonstrated changes in the SUMOylation status of metabolic enzymes and ion channels. In support of this, profound metabolic dysfunction, accelerated neuropathology, and sensory loss were observed in diabetic gene-targeted mice selectively lacking the ability to SUMOylate proteins in peripheral sensory neurons. TRPV1 function was impaired by diabetes-induced de-SUMOylation as well as by metabolic imbalance elicited by de-SUMOylation of metabolic enzymes, facilitating diabetic sensory loss. Our results unexpectedly uncover an endogenous post-translational mechanism regulating diabetic neuropathy in patients and mouse models that protects against metabolic dysfunction, nerve damage, and altered sensory perception.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32735781     DOI: 10.1016/j.neuron.2020.06.037

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  7 in total

Review 1.  Transient Receptor Potential (TRP) Channels in Head-and-Neck Squamous Cell Carcinomas: Diagnostic, Prognostic, and Therapeutic Potentials.

Authors:  Fruzsina Kiss; Krisztina Pohóczky; Arpad Szállási; Zsuzsanna Helyes
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

2.  Loss of POMC-mediated antinociception contributes to painful diabetic neuropathy.

Authors:  Nitin Agarwal; Thomas Fleming; Divija Deshpande; Claire Gaveriaux-Ruff; Christoph S N Klose; Anke Tappe-Theodor; Rohini Kuner; Peter Nawroth
Journal:  Nat Commun       Date:  2021-01-18       Impact factor: 14.919

3.  Tang Luo Ning, a Traditional Chinese Compound Prescription, Ameliorates Schwannopathy of Diabetic Peripheral Neuropathy Rats by Regulating Mitochondrial Dynamics In Vivo and In Vitro.

Authors:  Jiayue Zhu; Xinwei Yang; Xiao Li; Shuo Han; Yanbo Zhu; Liping Xu
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

Review 4.  Advances in TRP channel drug discovery: from target validation to clinical studies.

Authors:  Ari-Pekka Koivisto; Maria G Belvisi; Rachelle Gaudet; Arpad Szallasi
Journal:  Nat Rev Drug Discov       Date:  2021-09-15       Impact factor: 112.288

5.  Metabolomics and Microbiomics: New Potential Strategies in Chronic Pain Syndrome.

Authors:  Cristina Piras; Bruno Maria Pintus; Antonio Noto; Maurizio Evangelista; Vassilios Fanos; Mario Musu; Michele Mussap; Luigi Atzori; Salvatore Sardo; Gabriele Finco
Journal:  J Pain Res       Date:  2022-03-11       Impact factor: 3.133

6.  Paeoniflorin Upregulates Mitochondrial Thioredoxin of Schwann Cells to Improve Diabetic Peripheral Neuropathy Indicated by 4D Label-Free Quantitative Proteomics.

Authors:  Xinwei Yang; Xiao Li; Yanbo Zhu; YingYing Gao; Liping Xu
Journal:  Oxid Med Cell Longev       Date:  2022-03-18       Impact factor: 6.543

7.  Trophic factor BDNF inhibits GABAergic signaling by facilitating dendritic enrichment of SUMO E3 ligase PIAS3 and altering gephyrin scaffold.

Authors:  Zahra S Thirouin; Marta Figueiredo; Mohammad Hleihil; Raminder Gill; Giovanna Bosshard; R Anne McKinney; Shiva K Tyagarajan
Journal:  J Biol Chem       Date:  2022-03-17       Impact factor: 5.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.